Navigation Links
Team Develops Anti-Infection Technology

MORGANTOWN, W.Va., July 10 /PRNewswire-USNewswire/ -- Combat-related injuries have long plagued the military in part because of multidrug-resistant bacteria. Imagine being able to spray a compound fracture with microcapsules that deliver a drug to bolster the immune system, stopping infection before it starts.

That technology might be around the corner, says Bingyun Li, Ph.D., of the West Virginia University Department of Orthopaedics and director of the WVU Biomaterials, Bioengineering & Nanotechnology Laboratory. Li's team has developed a drug-delivery technology involving microcapsules - and a second technique, nanocoating - that have been shown to work in animal studies.

Results of the team's research involving the drug interleukin-12, a drug currently in anti-cancer clinical trials, has been published in the May issue of the journal Biomaterials. A deeper explanation of the approach, which could develop into an alternative to antibiotic therapy, is scheduled to be published in an upcoming issue of the Journal of Orthopaedic Research.

"These pioneering techniques could be important to the United States because of the wars in Iraq and Afghanistan," Li says. "The treatment of battlefield casualties is expensive, and the infection rate runs from 2 percent to 15 percent. In some cases, because the organisms have developed resistance, antibiotics don't work."

Outside the arena of warfare, millions of people could potentially be helped by the technology because infections can result whenever a biomedical device is implanted.

Li's team developed two ways to deliver interleukin-12.

The first is in microcapsules that can be injected or, potentially, delivered in a fine-mist spray directly to the site of an injury. The second is a nanocoating of interleukin-12 applied directly to stents, pacemakers, pain pumps, artificial limbs - virtually any biomedical device - before implantation. The coating is measured on the nano scale; one nanometer is one billionth of a meter.

"Interleukin-12 will maximize the body's natural response to an extent where infections can be prevented without the risk of the offending bacteria developing resistance to the treatment, as is becoming more of a problem with antibiotic therapy alone. With nanocoating, the drug is right where it needs to be - at the interface of the implant and your tissue," Li said. "With the microcapsule, the drug can be injected or sprayed where desired, and the nanocoating and microcapsule prolong the half-life of interleukin-12."

In both methods, because the interleukin-12 is delivered locally rather than spread throughout the body, as in antibiotic therapy, side effects are minimal, Li explained.

Li drew his team from the WVU Department of Orthopaedics, the WVU School of Pharmacy, the National Institute for Occupational Health and Safety (NIOSH), and the WVU Department of Microbiology, Immunology and Cell Biology.

Li, who is also a guest researcher with NIOSH, is giving a presentation on the technology later this summer to officials from the Naval Medical Research Center in Silver Spring, Maryland. He is also working with Christopher Kolanko, Ph.D., a Department of Defense consultant for the WVU Research Corporation, and program managers with the Department of Defense, to discuss further research possibilities and possible military applications.

Li's team has spent the past four years developing the technology, funded in part by the WVU Research Corporation, the National Science Foundation and the Osteosynthesis and Trauma Care Foundation.

This news release was issued on behalf of Newswise(TM). For more information, visit

SOURCE West Virginia University Health Sciences Center
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Couples more likely to divorce if spouse develops cervical or testicular cancer
2. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
3. UCLA doctor develops new technique to treat varicose veins
4. Biomarkers predict risk for invasive breast cancer years before the tumor develops
5. Silverchair Learning Systems Updates and Develops New Courses
6. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
7. Capsulated Systems, Inc. Develops Long Term Local Anesthetic
8. MIT develops thin-film micro pharmacy
9. Omron Healthcare Develops Solar-Powered Digital Blood Pressure Monitors
10. Psychologist develops post-operative care for heart patients in Bermuda
11. Medical Records Institute (MRI) Develops Initiative for EMRs Supporting Medicolegal Requirements
Post Your Comments:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology: